Researcher.Life Logo

Immunotherapy : Impact Factor & More

eISSN: 1750-7448pISSN: 1750-743X

Key Metrics

CiteScore
5.7
Eigenfactor
0.005 - 0.01
H-Index
59
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.7
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Immunotherapy

Immunotherapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher FUTURE MEDICINE LTD
Language English
Frequency Semi-monthly
General Details
LanguageEnglish
FrequencySemi-monthly
Publication Start Year2009
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Immunotherapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Immunotherapy

Evaluating inebilizumab in the treatment of generalized myasthenia gravis.
  • 25 Nov 2025
  • Immunotherapy
Ataxia Telangiectasia Mutated (ATM) gene alterations as biomarkers of response to immune checkpoint inhibitors.
  • 21 Nov 2025
  • Immunotherapy
Sublingual immunotherapy suppresses Th2-type immune response in the allergic rhinitis mouse model by inhibiting the activation of the NFκB pathway.
  • 20 Nov 2025
  • Immunotherapy
Simulating a virtual tumor board with large language models: a pilot study in NSCLC patients receiving immunotherapy.
  • 5 Nov 2025
  • Immunotherapy
Development of eosinophilic esophagitis during wheat oral immunotherapy in children: a retrospective cohort analysis.
  • 2 Nov 2025
  • Immunotherapy
Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials.
  • 1 Nov 2025
  • Immunotherapy
Evaluating inebilizumab in the treatment of generalized myasthenia gravis.
  • 25 Nov 2025
  • Immunotherapy
Ataxia Telangiectasia Mutated (ATM) gene alterations as biomarkers of response to immune checkpoint inhibitors.
  • 21 Nov 2025
  • Immunotherapy
Sublingual immunotherapy suppresses Th2-type immune response in the allergic rhinitis mouse model by inhibiting the activation of the NFκB pathway.
  • 20 Nov 2025
  • Immunotherapy
Simulating a virtual tumor board with large language models: a pilot study in NSCLC patients receiving immunotherapy.
  • 5 Nov 2025
  • Immunotherapy
Development of eosinophilic esophagitis during wheat oral immunotherapy in children: a retrospective cohort analysis.
  • 2 Nov 2025
  • Immunotherapy
Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials.
  • 1 Nov 2025
  • Immunotherapy

FAQs on Immunotherapy